Why Creating Transmissible Microbial Interferon Factories May Bring a Promise of a “Golden Era” in Future Human and Animal Health
Authors: Carp Theodor-Nicolae 
Published: February 2025

Transmissible microbial agents have brought utmost short-term and long-term concern for the public health sector due to the fact that they are generally highly capable of inducing serious consequences for the integrity of whole host organisms. Recently, it was discovered that the most important reason of their increasing capability and complexity of their immunopathogenesis capabilities represents their increased abilities of evading host immunity by undergoing direct and indirect levels of molecular self-camouflaging against host Pattern-Recognition Receptor, as well as the Type I and Type III Interferon-encoding genes. Clinical researchers developed medical approaches based on fairly low dosages of Type I Interferons for prophylactic and early therapeutic purposes against major infectious diseases like COVID-19, and the results were rather promising. Furthermore, scientists detected a high extent of immunostimulatory and immunomodulatory effects that such interferon glycoproteins bring upon the rest of the immune system. Essentially, they play a foundational role in the adequate activation of the immune system if they are produced in a timely manner. A developed medical approach against Diabetes Mellitus involving the exponential increase of the bioavailability of insulin via gene insertion into genomes of bacteria inoffensive to human and animal health may constitute a highly-matching model for the development of revolutionary vaccine candidates. Specifically, it may be important to consider the existence of candidate prophylactic and early therapeutic approaches implicating the allowance of environmental spread genetically-modified transmissible microbes with inserted human or animal Type I and/or Type III Interferon-encoding, as well as Pattern Recognition Receptor agonist protein-encoding genes that are attenuated on their genetic side responsible for induced pathogenesis and maintained pathophysiology, and perhaps not as much on their genetic side responsible for microbial reproduction and transmission. Perhaps, human and animal genes encoding recently-discovered fourth class of interferon glycoprotein can also be included in the equation of microbial gene insertion. An overall approach as such ought to occur during the first days of the autumn season, when common cold- and flu-inducing viruses only begin to spread from person to person. The overall objective is to thoroughly fill in the gap of immune evasion, which may only be possible if Type I and Type III Interferons are automatically produced and signalled to neighbouring cells and tissues by the exact time the first cells become infected. If such a candidate approach is proven to be successful, it would indicate that several pathogenic agents would start undergoing a &ldquo;Reverse Evolutionary&rdquo; process that could ultimately even result in their natural de-selection, due to the fact that strategic allowances of such microbes to spread in the local environments would lead to the domination of such genetically-modified microbes against wild-type microbes, and also due to the fact that the human interferon systems would become increasingly sensitised and be situated in a novel evolutionary curve of growth in relation to such microbial agents. In short, following extensive scientific and clinical research efforts, it may now be possible to create and evaluate transmissible vaccine candidates that aim to create a firm bridge between innate and adaptive immunity and that could bring widespread and unprecedentedly beneficial effects for human and animal health.